Cost‐Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate‐Alone Strategies in High‐Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide

Teriparatide, currently only available in brand form in the United States, is a costly drug approved for the treatment of postmenopausal osteoporotic women who are at high risk of fracture. Because market exclusivity for brand teriparatide expired in August 2019 in the US, we sought to understand th...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Takahiro, Crandall, Carolyn J, Ganz, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874180/
https://www.ncbi.nlm.nih.gov/pubmed/31768491
http://dx.doi.org/10.1002/jbm4.10233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874180/
https://www.ncbi.nlm.nih.gov/pubmed/31768491
http://dx.doi.org/10.1002/jbm4.10233

Ejemplares similares